Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
|Videos|February 23, 2019
Dr. Dandoy on TMA Risk After Pediatric Allogeneic Stem Cell Transplant
Author(s)Christopher E. Dandoy, MD, MSc
Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.
Advertisement
Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogeneic stem cell transplant are at high-risk of developing thrombotic microangiopathy (TMA).
TMA occurs in 30% of these patients and can occur as early as 7 days after transplant. When it is identified to be present, the patient can be properly treated right away, Dandoy notes.
Tools from these data presented at the 2019 Transplantation & Cellular Therapy Meetings as well as tools from other data can be used to identify these patients even earlier.
Advertisement
Related to this article
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
4
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
5